A Combined Treatment of Tamoxifen, Goserelin, and Sulindac in 2 Cases of Recurrent Desmoid Tumor in the Abdomen.
- Author:
Hee Cheol KIM
1
;
Byung Sun SUH
;
Dong Hee LEE
;
Byung Yool AHN
;
Choon Sik CHUNG
;
Gyeong hoon KANG
;
Hyun Kwon HA
;
Jin Cheon KIM
Author Information
1. Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Recurrent desmoid tumor;
Tamoxifen;
Goserelin;
Sulindac
- MeSH:
Abdomen*;
Deception;
Female;
Fibroma;
Fibromatosis, Aggressive*;
Goserelin*;
Humans;
Neoplasm Metastasis;
Pelvis;
Recurrence;
Sulindac*;
Tamoxifen*
- From:Journal of the Korean Society of Coloproctology
1999;15(4):339-343
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Desmoid tumor is a subtype of fibromatosis arising from deep fascial or soft tissue structure. It is characterized by locally aggressive behavior with a tendency to local recurrence, but is generally accepted the lack of ability for distant metastasis. Although excision is the best initial therapy, surgery is not always amenable in cases of lesions lying in difficult anatomical area. Two female patients with recurrent desmoid tumor in abdomen and pelvis after excision were treated with tamoxifen, goserelin, and sulindac. This therapy led to a progressive decrease of tumor size within 13 months in one patient. However, in the other patient, this combined therapy failed to reduce the size of the tumor. Despite the success of combined therapy with hormone and nonsteroidal anti-inflammatory drug is anecdotal, this treatment may improve the survival and reduce the recurrence in certain sub-group of desmoid tumor.
